The components of drug-linker conjugates for antibody drug conjugates (ADCs) are a cytotoxic drug that is active and a suitable linker. These conjugates can be used to create ADCs, which are highly selective and cytotoxic agents that are targeted for cancer cells after being joined to a monoclonal antibody.
The drug units in drug-linker conjugates are tubulin inhibitors and DNA damaging agents that have antitumor activity (i.e., ADC cytotoxins or payloads). Auristatins and Maytansinoids are the most widely used tubulin inhibitors, while Duocarmycins, Pyrrolobenzodiazepines, Camptothecines, and Daunorubicins/Doxorubicines are the most frequently used DNA damaging agents in ADCs. Additionally, a variety of conventional cytotoxic agents can be used in ADCs.
Cleavable and noncleavable ADC linkers are the two categories into which the majority of those currently undergoing clinical evaluation fall. Noncleavable linkers necessitate proteolytic degradation of the antibody component of the ADC in order to release the cytotoxic molecule, whereas cleavable linkers depend on cellular processes to release the toxin.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V127715 | 8-Arm-PEG20000-Methyl acrylate | 2451100-15-3 | |
|
V127716 | 8-Arm-PEG20000-Norbornene | ||
|
V127727 | 8-Arm-PEG40000-Acrylamide | ||
|
V127728 | 8-Arm-PEG40000-Acrylate | 2111799-19-8 | |
|
V127732 | 8-Arm-PEG40000-DBCO | ||
|
V127734 | 8-Arm-PEG40000-Methyl acrylate | 2451100-15-3 | |
|
V127735 | 8-Arm-PEG40000-Norbornene | ||
|
V77295 | Ac-Lys-Val-Cit-PABC-MMAE formic | Ac-Lys-Val-Cit-PABC-MMAE (formic) is part of the antibody conjugate active molecule ADC. | |
|
V128219 | Ac-RKAA-PABC-MMAE | 2768774-89-4 | Ac-RKAA-PABC-MMAE is a drug-linker conjugate used in antibody-drug conjugates (ADCs). |
|
V35242 | AcLysValCit-PABC-DMAE-SW-163D | 2411007-69-5 | AcLysValCit-PABC-DMAE-SW-163D is part of the active antibody coupling molecule (drug-linker conjugates for ADC), which is made up of natural dual intercalator SW-163D and linker AcLysValCitPABC-DMAE coupling. |
|
|
V110531 | ADC 38 drug linker | ADC 38 is a drug linker conjugate for antibody-drug conjugates (ADCs) that contains a CD4 mimic and a linker. | |
|
V128297 | ADC-5 drug-linker | ADC-5 drug-linker is a drug linker conjugate used in antibody-drug conjugates (ADCs) with potent antitumor activity. | |
|
V115115 | ADC-VI | 3031725-06-8 | ADC-VI (compound 6) is a conjugate of a toxic molecule and a linker, in which CPD6 carries the cytotoxic drug drutecan. |
|
V128719 | Amine-PEG8-Val-Cit-PAB-MMAE | 2879227-86-6 | Amine-PEG8-Val-Cit-PAB-MMAE is a highly effective antibody-drug conjugate (ADC). |
|
V88381 | Amino-PEG4-GGFG-Dxd | 2879227-88-8 | Amino-PEG4-GGFG-Dxd (Compound 13-7) is a drug-linker conjugate composed of Dxd and linker, which can be used for the synthesis of ADC. |
|
V88382 | Aminocaproyl-Val-Cit-PABC-MMAE | 1374407-35-8 | Aminocaproyl-Val-Cit-PABC-MMAE is a drug-linker conjugate used in the synthesis of ADC. |
|
V93149 | Aniline-PEG3-C1-Boc | 2115897-27-1 | Aniline-PEG3-C1-Boc (Compound D-1) is an intermediate for polymer-linked cytotoxic drugs. |
|
V118421 | APL-1082 | 2921735-93-3 | APL-1082 (Mc-exo-EVC-Exatecan) is a drug-linker conjugate that can be used in ADC synthesis. Its structure contains Exatecan (ADC payload) and a linker. |
|
V129270 | APL-1091 | 2921735-87-5 | APL-1091 is part of a drug linker conjugate for antibody-drug conjugates (ADCs). |
|
V104596 | APL-1092 | 2921735-91-1 | APL-1092 (Mal-Exo-EEVC-Exatecan) is a drug-linker complex that can be used for ADC synthesis. |